Martín Koretzky

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani et al. · The Lancet · 2023 · 151 citations · Full text

Hypertension, Renal Function, Renal Disease +10

Reference Values for Neutrophil to Lymphocyte Ratio (NLR), a Biomarker of Cardiovascular Risk, According to Age and Sex in a Latin American Population

E. Huguet, Gustavo Maccallini, P. Pardini et al. · Current Problems in Cardiology · 2019 · 44 citations

Inflammation, Vascular Disease, Cardiovascular Epidemiology +10

Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients

Sylvia Haas, Walter Ageno, Jeffrey I. Weitz et al. · Journal of Thrombosis and Haemostasis · 2019 · 41 citations · Full text

Acute Treatment, Thrombosis, Pulmonary Embolism +11

36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE

Alexander G.G. Turpie, Alfredo E. Farjat, Sylvia Haas et al. · Thrombosis Research · 2022 · 26 citations · Full text